ENA QUANTRIX 25 IgG at Test Zone Diagnostic Center

Understanding the ENA QUANTRIX 25 IgG Test

The ENA QUANTRIX 25 IgG is an advanced, highly specialized multiplex serological assay designed to detect and semi-quantitatively measure 25 distinct immunoglobulin G (IgG) autoantibodies directed against extractable nuclear antigens (ENA) and other cytoplasmic and nuclear cellular targets. This comprehensive autoimmune profile is a cornerstone in clinical immunology, providing clinicians with a detailed molecular map to assist in the differential diagnosis of systemic autoimmune rheumatic diseases (SARD). At Test Zone Diagnostic Center, this state-of-the-art diagnostic tool is utilized to evaluate patients presenting with complex, overlapping symptoms that suggest an underlying autoimmune pathology, such as Systemic Lupus Erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (scleroderma), mixed connective tissue disease (MCTD), and idiopathic inflammatory myopathies.

Autoimmune diseases occur when the body's immune system mistakenly identifies self-proteins as foreign invaders, producing autoantibodies that target healthy tissues. The ENA QUANTRIX 25 IgG panel utilizes advanced line immunoassay (LIA) or multiplex bead-based technology to screen for a broad spectrum of these autoantibodies simultaneously from a single blood sample. This multiplexing capability offers unparalleled diagnostic efficiency compared to traditional single-analyte testing, reducing turnaround times and providing a holistic view of the patient's autoantibody profile. The precise detection of these specific IgG antibodies not only aids in establishing an accurate diagnosis but also plays a vital role in prognostic stratification, risk assessment for organ involvement, and monitoring disease activity over time.

Clinical Procedure: What to Expect

Patient Preparation

Preparing for the ENA QUANTRIX 25 IgG test at Test Zone Diagnostic Center is straightforward, as it is a non-invasive blood-based investigation. Patients are advised to observe the following guidelines to ensure optimal sample quality and accurate results:

• No Fasting Required: Fasting is generally not mandatory for this specific immunological test. Patients can consume food and drinks normally prior to sample collection.
• Medication Review: It is critical to inform the ordering physician and the laboratory staff about all current medications, particularly immunosuppressants, corticosteroids, or biologic therapies, as these can potentially suppress autoantibody levels and influence the test results.
• Hydration: Staying well-hydrated by drinking plenty of water before the blood draw makes venipuncture easier and more comfortable.
• Avoid Strenuous Activity: While not strictly prohibited, avoiding extreme physical exertion immediately before the test is recommended to maintain baseline physiological states.

During the Procedure

The collection of the blood sample for the ENA QUANTRIX 25 IgG test is performed by highly trained phlebotomists at Test Zone Diagnostic Center, adhering to strict clinical and safety protocols:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair, and the arm is positioned to expose the antecubital fossa (the bend of the elbow).
• Site Selection and Sanitization: The phlebotomist identifies a suitable vein, typically the median cubital vein, and cleanses the skin thoroughly with an antiseptic solution (such as 70% isopropyl alcohol) to prevent contamination.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. A vacuum collection tube (typically a serum separator tube or SST with a gold or red top) is attached to collect the required volume of blood.
• Duration: The actual blood draw takes less than two minutes. The entire process, including registration and post-draw care, is completed within 10 to 15 minutes.
• Post-Procedure Care: Once the sample is collected, the needle is withdrawn, and gentle pressure is applied to the puncture site with a sterile cotton ball or gauze. An adhesive bandage is applied to prevent minor bruising or bleeding.
• Safety Considerations: All materials used are sterile and disposable, eliminating any risk of cross-contamination. Patients may feel a brief, mild pinch during needle insertion, but the procedure is generally well-tolerated and safe.

When is an ENA QUANTRIX 25 IgG Performed?

Suspected Systemic Lupus Erythematosus (SLE)

Physicians frequently order the ENA QUANTRIX 25 IgG test when a patient presents with classic symptoms of Systemic Lupus Erythematosus. These symptoms include a characteristic malar (butterfly) rash across the cheeks and bridge of the nose, photosensitivity, unexplained joint pain and swelling, chronic fatigue, and recurrent low-grade fevers. Because SLE can affect multiple organ systems, including the kidneys, heart, and central nervous system, early and precise detection of specific autoantibodies like anti-double-stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) is crucial for initiating timely therapeutic interventions and preventing irreversible organ damage.

Evaluation of Sjogren's Syndrome

Sjogren's syndrome is a chronic autoimmune disorder characterized by the destruction of exocrine glands, primarily leading to severe dryness of the eyes (keratoconjunctivitis sicca) and mouth (xerostomia). Clinicians utilize the ENA QUANTRIX 25 IgG panel to evaluate patients experiencing these debilitating dry symptoms, along with systemic manifestations such as joint pain, profound fatigue, and peripheral neuropathy. The presence of specific autoantibodies, notably anti-SSA (Ro) and anti-SSB (La), provides strong diagnostic evidence supporting Sjogren's syndrome, helping to differentiate it from other causes of dry eyes and mouth.

Diagnosis of Systemic Sclerosis (Scleroderma)

Systemic sclerosis is a complex connective tissue disease characterized by progressive fibrosis of the skin and internal organs, alongside vascular abnormalities. The ENA QUANTRIX 25 IgG test is indicated for patients presenting with Raynaud's phenomenon (exaggerated cold sensitivity in fingers and toes), skin thickening starting in the fingers (sclerodactyly), difficulty swallowing, or unexplained shortness of breath. By identifying specific markers such as anti-Scl-70 (topoisomerase I) and anti-centromere antibodies, the test helps clinicians distinguish between limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis, which carry different prognostic implications and risks for pulmonary hypertension or interstitial lung disease.

Investigation of Inflammatory Myopathies (Myositis)

Inflammatory myopathies, including polymyositis and dermatomyositis, present with progressive muscle weakness, particularly in the proximal muscles (shoulders and hips), difficulty climbing stairs or lifting objects, and sometimes characteristic skin rashes (such as Gottron's papules or a heliotrope rash). The ENA QUANTRIX 25 IgG panel includes critical myositis-specific and myositis-associated autoantibodies, such as anti-Jo-1, anti-Mi-2, and anti-SRP. Detecting these antibodies is essential for confirming a diagnosis of inflammatory myopathy, predicting potential lung or cardiac involvement, and guiding immunosuppressive treatment strategies.

Mixed Connective Tissue Disease (MCTD) Differentiation

Mixed Connective Tissue Disease is an overlap syndrome that combines clinical features of SLE, systemic sclerosis, and polymyositis. Patients often present with a complex array of symptoms, including swollen hands, joint pain, Raynaud's phenomenon, and muscle inflammation. The ENA QUANTRIX 25 IgG test is highly valuable in this clinical scenario, as the presence of high titers of anti-U1-RNP (ribonucleoprotein) antibodies in the absence of other SARD-specific antibodies is the defining serological hallmark of MCTD, allowing for a precise and distinct diagnosis.

What Does an ENA QUANTRIX 25 IgG Detect?

The ENA QUANTRIX 25 IgG panel is designed to detect a comprehensive array of autoantibodies, each associated with specific clinical phenotypes and autoimmune conditions. The panel evaluates the presence of the following key autoantibodies:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE); strongly correlated with lupus nephritis and disease activity.
• Anti-Smith (Sm): Considered pathognomonic for SLE; included in the classification criteria for the disease.
• Anti-U1-RNP: The primary diagnostic marker for Mixed Connective Tissue Disease (MCTD); also found in some SLE patients.
• Anti-SSA (Ro60): Associated with Sjogren's syndrome, SLE, and neonatal lupus erythematosus.
• Anti-Ro52 (TRIM21): Frequently detected in Sjogren's syndrome, systemic sclerosis, and inflammatory myopathies; associated with interstitial lung disease.
• Anti-SSB (La): Strongly associated with Sjogren's syndrome and often co-exists with anti-SSA antibodies.
• Anti-Scl-70: Specific for diffuse cutaneous systemic sclerosis; associated with an increased risk of interstitial lung disease.
• Anti-Cenp A & B (Centromere): Markers for limited cutaneous systemic sclerosis (formerly CREST syndrome); associated with pulmonary arterial hypertension.
• Anti-Jo-1: The most common anti-synthetase antibody; associated with polymyositis, dermatomyositis, interstitial lung disease, and arthritis.
• Anti-Mi-2: Highly specific for dermatomyositis; typically associated with a favorable response to therapy and lower risk of interstitial lung disease.
• Anti-Ku: Found in overlap syndromes involving systemic sclerosis, myositis, and SLE.
• Anti-PM-Scl100 & PM-Scl75: Associated with polymyositis/systemic sclerosis overlap syndrome.
• Anti-SRP (Signal Recognition Particle): Associated with necrotizing autoimmune myopathy, characterized by severe, rapidly progressive muscle weakness.
• Anti-PL-7 & PL-12: Anti-synthetase antibodies associated with myositis and severe interstitial lung disease.
• Anti-EJ & OJ: Rare anti-synthetase antibodies associated with myositis and lung involvement.
• Anti-Ribosomal P: Highly specific for SLE; associated with neuropsychiatric lupus, lupus hepatitis, and nephritis.
• Anti-PCNA (Proliferating Cell Nuclear Antigen): Found in a small percentage of SLE patients; associated with lupus nephritis.
• Anti-AMA-M2 (Antimitochondrial): The hallmark marker for Primary Biliary Cholangitis (PBC); useful in detecting overlap syndromes.
• Anti-DFS70: Often found in healthy individuals; when present in isolation, it helps rule out systemic autoimmune rheumatic diseases.
• Anti-Nucleosome: Highly specific marker for SLE; correlates with renal involvement and disease activity.
• Anti-Histone: Associated with drug-induced lupus erythematosus as well as idiopathic SLE.
• Anti-gp210 & sp100: Specific markers for Primary Biliary Cholangitis, particularly useful in AMA-negative cases.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely diagnostic results are crucial for patient management and peace of mind. The ENA QUANTRIX 25 IgG is a highly complex, specialized immunological assay requiring meticulous laboratory processing, quality control, and clinical validation. Typically, the results for this comprehensive panel are finalized within 3 to 5 working days from the time of sample collection.

Once the analysis is complete, the report undergoes a rigorous multi-step verification process by our consultant pathologists and clinical immunologists to ensure absolute accuracy. Patients and referring physicians can access the reports conveniently through our secure online portal, via email, or by visiting our diagnostic center. An automated SMS notification is sent to the patient's registered mobile number as soon as the report is ready for download.

ENA QUANTRIX 25 IgG Findings Overview

The following table provides a general overview of the parameters evaluated in the ENA QUANTRIX 25 IgG panel, along with typical normal and possible abnormal clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA IgG	Negative	Positive (Highly suggestive of SLE / Lupus Nephritis)
Anti-Smith (Sm) IgG	Negative	Positive (Specific for Systemic Lupus Erythematosus)
Anti-U1-RNP IgG	Negative	Positive (Indicative of Mixed Connective Tissue Disease)
Anti-SSA (Ro60) / SSB (La) IgG	Negative	Positive (Suggestive of Sjogren's Syndrome or SLE)
Anti-Scl-70 IgG	Negative	Positive (Associated with Diffuse Systemic Sclerosis)
Anti-Centromere (Cenp A/B) IgG	Negative	Positive (Associated with Limited Systemic Sclerosis)
Anti-Jo-1 IgG	Negative	Positive (Indicative of Anti-Synthetase Syndrome / Myositis)
Anti-Ribosomal P IgG	Negative	Positive (Associated with Neuropsychiatric Lupus)
Anti-AMA-M2 IgG	Negative	Positive (Associated with Primary Biliary Cholangitis)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for ENA QUANTRIX 25 IgG?

• Experienced Healthcare Professionals: Our clinical laboratory is staffed by highly qualified pathologists, immunologists, and medical technologists specializing in autoimmune diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the diagnostic journey.
• Quality Diagnostic Services: We adhere to stringent internal and external quality control programs to ensure the highest standards of diagnostic accuracy.
• Professional Reporting: Our reports are comprehensive, easy to read, and validated by senior clinical specialists.
• Modern Diagnostic Approach: We utilize advanced multiplex immunoassay platforms to deliver precise, detailed autoantibody profiles.
• Comfortable Environment: Our state-of-the-art collection centers are designed to provide a stress-free and hygienic experience for patients.
• Convenient Location: Easily accessible facilities with ample parking and comfortable waiting areas.
• Commitment to Accurate Diagnosis: We are dedicated to providing reliable, evidence-based diagnostic insights to support effective clinical decision-making.